The 'answer' to the national petition urging insurance coverage for the next-generation ADC anti-cancer drug Enhertu is expected to come out soon. According to the related industry, Daiichi Sankyo Korea and AstraZeneca Korea's HER2-positive breast cancer treatment, Antibody-drug conjugate (ADC) Enhertu, will be submitted to the Petition Review Subcommittee next week. As a result, attention is paid to how it will affect the Enhertu benefit listing process. The drug was referred to the Health and Welfare Committee of the National Assembly last month after a petition urging health insurance approval at the beginning of this year gained the consent of 50,000 people. Enhertu, based on the DESTINY-Breast01 and DESTINY-Gast